Invitrogen puts up $57M for CellzDirect buyout

Invitrogen is buying out CellzDirect in a $57 million cash deal. CellzDirect provides R&D operations hepatocyte-based cell products and other services used to test new drugs. Primary human hepatocytes can be used to predict a compound's effects on enzymatic metabolism in the liver, helping to avoid trial failures. CellzDirect was set up seven years ago and has facilities in North Carolina and Austin.

- check out the release for more info

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.